Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

BACKGROUND: Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP). METHODS: Ipilimumab was available upon physician request for patients aged 16 or over with pretreated sta...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Ascierto, Paolo A, Simeone, Ester, Sileni, Vanna Chiarion, Pigozzo, Jacopo, Maio, Michele, Altomonte, Maresa, Del Vecchio, Michele, Di Guardo, Lorenza, Marchetti, Paolo, Ridolfi, Ruggero, Cognetti, Francesco, Testori, Alessandro, Bernengo, Maria Grazia, Guida, Michele, Marconcini, Riccardo, Mandalà, Mario, Cimminiello, Carolina, Rinaldi, Gaetana, Aglietta, Massimo, Queirolo, Paola
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2014
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4030525/
https://ncbi.nlm.nih.gov/pubmed/24885479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-116
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन